SCHEMBL630627

SCHEMBL630627

C=Cc1cc(OC)ccc1CO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.43
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 2/20 0.43
TRIM24 O15164 1/20 0.40
TYR P14679 1/20 0.40
TRIM33 Q9UPN9 1/20 0.40
APLNR P35414 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
KMT2A Q03164 1/20 0.39
JUN P05412 1/20 0.39
NFKB1 P19838 1/20 0.39
CYP1A1 P04798 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP1B1 Q16678 2/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16959550 0.84 ERN1 (0.44) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL629324 0.82 ERN1 (0.40) ERN1ALDH1A1KDM4ETRIM24TYR
SCHEMBL16953704 0.81 ERN1 (0.39) ERN1ALDH1A1KDM4EAPLNRKMT2A
SCHEMBL630820 0.79 ABCB11 (0.36) ERN1ALDH1A1KDM4EKMT2ACYP1A1
SCHEMBL630819 0.79 ABCB11 (0.36) ERN1ALDH1A1KDM4EKMT2ACYP1A1
SCHEMBL20767542 0.77 LTA4H (0.51) ALDH1A1CYP11B1CYP11B2
SCHEMBL29216334 0.77 POLB (0.48) ERN1ALDH1A1KDM4ECYP11B1CYP11B2
SCHEMBL9065566 0.77 CYP1A2 (0.52) ERN1ALDH1A1KDM4ETRIM24TYR
SCHEMBL30567454 0.77 CYP1A2 (0.52) ERN1ALDH1A1KDM4ETRIM24TYR
SCHEMBL2061056 0.77 KDM4E (0.50) ALDH1A1KDM4EAPLNRCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963292-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-02-22 EP disclosed
US-7700633-B2 Organic compounds NOVARTIS AG (CH) 2010-04-20 US disclosed
US-20080262050-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-23 US disclosed
EP-1963292-A2 ORGANIC COMPOUNDS Novartis Pharma AG (CH) 2008-09-03 EP disclosed
WO-2007067615-A2 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262050-A1 Organic Compounds PTPRS, PTPRO, PTPRC ERN1 3196/4885ALDH1A1 2690/4885KDM4E 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.